Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.
about
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Optimal management of breast cancer in the elderly patient: current perspectivesTrastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.
P2860
Q26864094-0857B317-A0D0-459E-9CFA-47CFCAFEE14CQ27025860-5326F513-B2B3-4FA2-9141-C81CBC57421CQ27690879-F27F8CDD-C6F5-452B-A5F4-80BA1F94552BQ31004660-0B775F6F-5D4E-4DEE-96E4-4DA0F6322A23Q37612139-4A3F60EB-C39C-4AC8-B8BE-06B303E5E81DQ37746911-9AA6CA51-40D8-4320-BEEC-25CCE47DD269Q38896955-4ED49705-E596-4D1E-AC6F-1551350D11ADQ38978030-4BCD5B53-AEC2-4BF0-B1F3-F0D90CFF6045Q40583931-A6174A48-79EC-4885-B215-0ABB23BA5F18Q41288150-61C1B284-0213-4A45-8749-0A062E299A95Q51132740-84DC1358-B21B-4CFD-BD8C-DE114C1DF010
P2860
Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk of cardiovascular adverse ...... cer: a population-based study.
@ast
Risk of cardiovascular adverse ...... cer: a population-based study.
@en
Risk of cardiovascular adverse events from trastuzumab
@nl
type
label
Risk of cardiovascular adverse ...... cer: a population-based study.
@ast
Risk of cardiovascular adverse ...... cer: a population-based study.
@en
Risk of cardiovascular adverse events from trastuzumab
@nl
prefLabel
Risk of cardiovascular adverse ...... cer: a population-based study.
@ast
Risk of cardiovascular adverse ...... cer: a population-based study.
@en
Risk of cardiovascular adverse events from trastuzumab
@nl
P2093
P2860
P1476
Risk of cardiovascular adverse ...... ncer: a population-based study
@en
P2093
A L Potosky
A N Freedman
J L Warren
P2860
P2888
P304
P356
10.1007/S10549-014-2836-7
P407
P50
P577
2014-01-28T00:00:00Z
P6179
1030373739